ADCT vs. CGEM, LENZ, PHAR, ABUS, IMNM, EOLS, AUTL, ERAS, ORIC, and VECT
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), Pharming Group (PHAR), Arbutus Biopharma (ABUS), Immunome (IMNM), Evolus (EOLS), Autolus Therapeutics (AUTL), Erasca (ERAS), ORIC Pharmaceuticals (ORIC), and VectivBio (VECT). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs.
Cullinan Therapeutics (NASDAQ:CGEM) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.
Cullinan Therapeutics presently has a consensus target price of $31.67, suggesting a potential upside of 208.64%. ADC Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 340.77%. Given ADC Therapeutics' higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Cullinan Therapeutics.
ADC Therapeutics received 16 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 67.44% of users gave ADC Therapeutics an outperform vote.
Cullinan Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cullinan Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 1 mentions for ADC Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.83 beat ADC Therapeutics' score of -1.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media.
86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cullinan Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Cullinan Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.
Summary
Cullinan Therapeutics beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 1/18/2025 by MarketBeat.com Staff
Free ADCT Stock Alerts